US FDA, EU join forces to streamline generic bioequivalence study inspections
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration and the European Medicines Agency plan to start the New Year by joining forces to streamline information sharing on inspections of bioequivalence studies conducted and planned for generic drug applications1,2.